• 1
    Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med. 2010; 363: 653-662.
  • 2
    Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004; 104: 3483-3489.
  • 3
    Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010; 28: 1611-1615.
  • 4
    Meyer RM, Gospodarowicz MK, Connors JM, et al; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012; 366: 399-408.
  • 5
    Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010; 363: 640-652.
  • 6
    Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009; 361: 849-857.
  • 7
    Bestawros A, Foltz L, Srour N, Connors JM. Patients' versus physicians' roles in detecting recurrent Hodgkin lymphoma. J Clin Oncol. 29: 2011; (suppl; abstr 8041).
  • 8
    Foltz LM, Song KW, Connors JM. Who actually detects relapse in Hodgkin lymphoma: patient or physician? ASH Annual Meeting Abstracts. 2004; 104: 853a-854a.
  • 9
    Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997; 314: 343-346.
  • 10
    Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 1997; 15: 1123-1130.
  • 11
    Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010; 116: 3835-3842.
  • 12
    Cheson B. The case against heavy PETing. J Clin Oncol. 2009; 27: 1742-1743.
  • 13
    Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20(suppl 4): 108-109.
  • 14
    Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012; 119: 4123-4128.
  • 15
    Portlock CS, Donnelly GB, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004; 125: 701-708.
  • 16
    Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 7: 1630-1636.
  • 17
    Meyer RM, Gospodarowicz MK, Connors JM, et al; National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 4634-4642.
  • 18
    Olcese F, Clavio M, Rossi E, et al. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. Ann Hematol. 2009; 88: 855-861.
  • 19
    Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001; 19: 4238-4244.
  • 20
    Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004; 22: 2835-2841.
  • 21
    Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006; 24: 3128-3135.
  • 22
    Ferme C, Eghbali H, Meerwaldt JH, et al; EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007; 357: 1916-1927.
  • 23
    Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol. 1998; 16: 830-843.
  • 24
    Young RC, Canellos GP, Chabner BA, Hubbard SM, DeVita VT Jr. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer. 1978; 42(suppl 2): 1001-1007.
  • 25
    Wagner-Johnston ND, Bartlett NL. Role of routine imaging in lymphoma. J Natl Compr Canc Netw. 2011; 9: 575-584.
  • 26
    Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011; 90: 165-171.
  • 27
    National Comprehensive Cancer Network. Hodgkin lymphoma. In: NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA: National Comprehensive Cancer Network; 2011: 15.
  • 28
    Ng A, Constine LS, Advani R, et al. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer. 2010; 34: 211-227.
  • 29
    Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol. 2006; 24: 4116-4122.
  • 30
    Hodgson DC, Grunfeld E, Gunraj N, Del Giudice L. A population-based study of follow-up care for Hodgkin lymphoma survivors: opportunities to improve surveillance for relapse and late effects. Cancer. 2010; 116: 3417-3425.
  • 31
    Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007; 25: 3746-3752.
  • 32
    Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009; 27: 1906-1914.
  • 33
    Fanti S, Castellucci P, Stefoni V, et al. Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. Ann Nucl Med. 2008; 22: 429-432.
  • 34
    Gallamini A, Biggi A, Chauvie S, et al. Does a negative post-therapy PET obviate the need for any further follow-up imaging in patients with nonbulky early-stage Hodgkin's lymphoma (HL)? ASCO Meeting Abstracts. 2010; 28: 8058.